Arcus Biosciences, Inc.
RCUS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $26 | $160 | $28 | $26 |
| % Growth | -83.8% | 471.4% | 7.7% | – |
| Cost of Goods Sold | $2 | $0 | $0 | $0 |
| Gross Profit | $24 | $160 | $28 | $26 |
| % Margin | 92.3% | 100% | 100% | 100% |
| R&D Expenses | $141 | $139 | $122 | $101 |
| G&A Expenses | $27 | $29 | $28 | $28 |
| SG&A Expenses | $27 | $29 | $28 | $28 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2 | $0 | $0 | $0 |
| Operating Expenses | $166 | $168 | $150 | $129 |
| Operating Income | -$142 | -$8 | -$122 | -$103 |
| % Margin | -546.2% | -5% | -435.7% | -396.2% |
| Other Income/Exp. Net | $7 | $0 | $10 | $9 |
| Pre-Tax Income | -$135 | -$8 | -$112 | -$94 |
| Tax Expense | $0 | $0 | $0 | $1 |
| Net Income | -$135 | -$8 | -$112 | -$94 |
| % Margin | -519.2% | -5% | -400% | -361.5% |
| EPS | -1.27 | 0.043 | -1.14 | -1.03 |
| % Growth | -3,026.3% | 103.8% | -10.7% | – |
| EPS Diluted | -1.27 | 0.043 | -1.14 | -1.03 |
| Weighted Avg Shares Out | 107 | 106 | 98 | 92 |
| Weighted Avg Shares Out Dil | 107 | 107 | 98 | 92 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10 | $10 | $11 | $12 |
| Interest Expense | $3 | $2 | $1 | $2 |
| Depreciation & Amortization | $2 | $2 | $3 | $3 |
| EBITDA | -$130 | $4 | -$108 | -$89 |
| % Margin | -500% | 2.5% | -385.7% | -342.3% |